Clinical trial
A Study of ARRY-520 in Patients With Advanced Cancer
NCT00462358 · Array Biopharma, now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00462358 |
|---|---|
| Title | A Study of ARRY-520 in Patients With Advanced Cancer |
| Lead sponsor | Array Biopharma, now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Advanced Solid Tumors |
| Intervention type | Drug |
| Interventions | ARRY-520, KSP(Eg5) inhibitor, intravenous, Filgrastim, granulocyte-colony stimulating factor (G-CSF), subcutaneous |
| Enrollment | 41 |
| Start date | Apr 1, 2007 |
| Primary completion | Nov 1, 2010 |
| Completion | Nov 1, 2010 |
| First posted | Apr 19, 2007 |
| Last update posted | Sep 28, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: